Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Blood

Volumn 130, Issue 3, 2017, Pages 267-270

  Zinzani, Pier Luigi ^a   Ribrag, Vincent ^b   Moskowitz, Craig H ^c   Michot, Jean Marie ^b   Kuruvilla, John ^d   Balakumaran, Arun ^e   Zhang, Yayan ^e   Chlosta, Sabine ^e   Shipp, Margaret A ^f   Armand, Philippe ^f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e MERCK RESEARCH LABORATORIES   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE PLUS DOXORUBICIN PLUS ETOPOSIDE PLUS PREDNISOLONE PLUS RITUXIMAB PLUS VINCRISTINE; CYCLOPHOSPHAMIDE PLUS DOXORUBICIN PLUS ETOPOSIDE PLUS PREDNISOLONE PLUS VINCRISTINE; CYCLOPHOSPHAMIDE PLUS DOXORUBICIN PLUS PREDNISOLONE PLUS RITUXIMAB PLUS VINCRISTINE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; OXALIPLATIN; PEMBROLIZUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL OUTCOME; COHORT ANALYSIS; DECREASED APPETITE; DIARRHEA; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTHYROIDISM; LIVER VENOOCCLUSIVE DISEASE; MALE; MEDIASTINUM CANCER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY MEDIASTINAL B CELL LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION PNEUMONIA; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; GENE EXPRESSION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEDIASTINAL NEOPLASMS; METABOLISM; MORTALITY; PATIENT SAFETY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATIENT SAFETY; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85026300380     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-12-758383     Document Type: Article

References (18)

1. Bhatt VR, Mourya R, Shrestha R, Armitage JO. Primary mediastinal large B-cell lymphoma. Cancer Treat Rev. 2015;41(6):476-485.
2. Martelli M, Di Rocco A, Russo E, Perrone S, Foà R. Primary mediastinal lymphoma: diagnosis and treatment options. Expert Rev Hematol. 2015; 8(2):173-186.
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program website. Available from URL: http://seer.cancer.gov/. Accessed 20 February 2017.
4. Petković I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn). 2015;19(6):428-435.
5. Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997;15(4):1646-1653.
6. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008; 49(7):1329-1336.
7. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
8. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
9. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38(12):1715-1723.
10. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13): 2062-2065.
11. Van Roosbroeck K, Ferreiro JF, Tousseyn T, et al. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. Genes Chromosomes Cancer. 2016;55(5):428-441.
12. Reck M, Rodríguez-Abreu D, Robinson AG, et al; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833.
13. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-2532.
14. Armand P, Shipp MA, Ribrag V, et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016;34(31):3733-3739.
15. Freshwater T, de Greef R, Kondic A, et al. Assessment of pembrolizumab (MK-3475) dosing strategy based on population pharmacokinetics and exposure-response models. J Pharmacokinet Pharmacodynam. 2015;42:S15.
16. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
17. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc. htm. Accessed 20 February 2017.
18. Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16): 2328-2330.